Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease

Published:2017-10 Issue:10 Volume:23 Page:1762-1773
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Cheng Julianna,Hamilton Zachary,Smyth Matthew,Barker Collin,Israel David,Jacobson Kevan

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference50 articles.

1. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

2. Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease

3. Outcome Following Infliximab Therapy in Children With Ulcerative Colitis

4. Anti-infliximab antibodies in inflammatory bowel disease

5. A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22

2. Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort;Inflammatory Bowel Diseases;2023-11-27

3. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2023-10-17

4. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn’s disease patients treated by combination treatment with infliximab and azathioprine;Alimentary Pharmacology & Therapeutics;2022-01-14

5. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis;Journal of Clinical Medicine;2021-05-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3